The TQT study, since its implementation in 2005, has been a target for criticism due to the increased cost of drug development. For the last 10 years, more efficient approaches to reduce the associated costs and alternatives to a conventional TQT study have been extensively discussed. Sara Fernandes, Medical Writer and Jorg Taubel, Medical Practitioner and CEO of Richmond Pharmacology, submit a white paper with Professor A. John Camm on assay sensitivity in QT assessment, discussing its studies in the regulatory environment and mentioning non-pharmacological approaches.
https://www.jforcs.com/7/wp-content/uploads/2016/01/Assay…-1.pdf